PDCD1 and central nervous system cancer: Targeting CAA-derived CXCL8 sensitized TNBC to anti-PD-1 immunotherapy[79], which is consistent with data from the literature showing its role in inhibiting anti-PD-1 therapy in glioma[79-81] [Table 4].